

# Lucie Nekvindová

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6638113/publications.pdf>

Version: 2024-02-01

10  
papers

145  
citations

1684188

5  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

276  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. <i>Arthritis Care and Research</i> , 2022, 74, 1205-1218.	3.4	20
2	Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210816.	2.7	1
3	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. <i>Rheumatology International</i> , 2022, 42, 803-814.	3.0	3
4	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 4741-4751.	1.9	6
5	Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , 2021, 23, 11.	3.5	5
6	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1410-1418.	0.9	28
7	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 183-192.	3.1	5
8	Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLEAR Study by the Czech CLL Study Group. <i>Hematological Oncology</i> , 2020, 38, 509-516.	1.7	7
9	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	5.7	47
10	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. <i>Rheumatology International</i> , 2019, 39, 469-478.	3.0	23